Chemometec A/S Raises FY27 Revenue and EBITDA Guidance amid Strong Q1 Performance

Chemometec A/S, a Danish life‑sciences tools and services company listed on the OMX Nordic Exchange Copenhagen, announced a significant upward revision of its revenue and operating profit forecasts for the fiscal year 2026/27. The update follows a robust first‑quarter performance that exceeded market expectations and aligns with the company’s broader strategy to expand its portfolio of automated cell‑counting instruments and associated consumables.

Key Highlights of the Guidance Upgrade

  • Revenue Outlook – The company has lifted its revenue forecast for FY27, reflecting increased demand for its NucleoCounter series and the Xcyto quantitative cell imager across sectors such as cell therapeutics, stem cell research, and bioprocessing.
  • EBITDA Projection – Operating profit guidance has also been raised, indicating stronger cost management and higher margin contributions from high‑value consumables and software licensing (e.g., NucleoView).
  • Q1 Performance – First‑quarter results, released on 5 October 2026, showed revenue growth and improved operating margins, reinforcing confidence in the upward revisions.

Market Reaction

Shares of Chemometec traded at DKK 550.5 on 1 October 2026, with a 52‑week range between DKK 804 and DKK 235.2. Following the guidance update, the stock experienced a modest uptick, buoyed by investor sentiment that the company is capitalizing on its strong product pipeline and market leadership in cell‑counting solutions.

Share Buyback Completion

In a related development, Chemometec completed a share‑buyback programme on 2 October 2026. The buyback, announced by the company on the Nasdaq OMX Nordic platform, aimed to return capital to shareholders and support the share price. The completion of this programme underscores the company’s confidence in its long‑term value creation.

Industry Context

Chemometec’s products—ranging from the NucleoCounter NC‑3000 image cytometer to the NucleoCounter SP‑100 sperm cell counter—serve critical roles in research and quality control across a spectrum of applications, including:

  • Cell Therapeutics & Stem Cell Research – High‑precision viability and counting tools are essential for therapeutic product development.
  • Cancer Cell Research – Accurate cell characterization supports drug discovery and biomarker studies.
  • Bioprocessing & Toxicology – Reliable cell counts and viability metrics are mandatory for process validation and safety assessments.
  • Agricultural & Food Analytics – Somatic cell counters (SCC‑100, SCC‑400) aid in milk quality control, while yeast counters (YC‑100) support fermentation monitoring.

The company’s diversified product range, coupled with consumables and accessories, generates recurring revenue streams that contribute to its operating profit.

Outlook

With the upgraded guidance and the completion of its buyback programme, Chemometec is positioned to leverage its market-leading technology portfolio while delivering shareholder value. The company’s focus on expanding its software ecosystem and enhancing customer support is expected to sustain revenue growth throughout FY27 and beyond.